Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone sublingual tablets for cognitive impairment associated with cerebral small vessel disease
ChiCTR2400094236Phase 3Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edaravone in Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: MoCA scores. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
edaravone
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on ChiCTR2400094236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094236.